Spectral domain optical coherence tomography changes following intravitreal dexamethasone implant, Ozurdex® in patients with uveitic cystoid macular edema

被引:19
|
作者
Bansal, Pooja [1 ]
Agarwal, Aniruddha [2 ]
Gupta, Vishali [1 ]
Singh, Ramandeep [1 ]
Gupta, Amod [1 ]
机构
[1] Postgrad Inst Med Educ & Res, Adv Eye Ctr, Dept Ophthalmol, Chandigarh 160012, India
[2] Univ Nebraska Med Ctr, Stanley M Truhlsen Eye Inst, Omaha, NE USA
关键词
Cystoid macular edema; dexamethasone implant; external limiting membrane; optical coherence tomography; Ozurdex; serous retinal detachment; uveitis; FOVEAL PHOTORECEPTOR LAYER; INNER/OUTER SEGMENT JUNCTION; VISUAL-ACUITY; RESOLUTION; INTEGRITY; ASSOCIATION; THERAPY; IMPACT; EYES;
D O I
10.4103/0301-4738.159870
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To correlate the structural and functional changes following intravitreal injection of dexamethasone 0.7 mg (Ozurdex (R)) implant in patients with recalcitrant uveitic cystoid macular edema (CME). Materials and Methods: In a prospective, interventional, nonrandomized study, 30 eyes (27 patients) with uveitic CME received Ozurdex (R) implant and were followed-up for 24 weeks at periodic intervals to monitor structural alterations seen on spectral domain optical coherence tomography (SD-OCT). The outcome measures included change in central macular thickness (CMT) and best-corrected visual acuity (BCVA) as well as structural alterations seen on OCT such as change in the height of cystoid spaces (CSs) and sub-foveal serous retinal detachment (SSRD). The integrity of external limiting membrane and inner-outer segment junction was assessed at baseline and follow-up visits. Results: Mean age of the patients was 46.09 +/- 15.66 years. The mean CMT decreased by 96 mu m at 1-day, 231.64 mu m at 1-week, 254.21 mu m at 4 weeks and 249.14 mu m at 12 weeks (P < 0.001) compared with baseline. BCVA improved from a baseline mean of 0.62 LogMAR units to 0.49 on day 1 to 0.31 at 24 weeks (P < 0.001). A decrease in the mean height of CS, that is, 133.28 mu m from a baseline of 317.71 mu m was noted on the 1st day (P < 0.001). 4 eyes demonstrated the presence of CS at 4 weeks, 1 eye at 6 weeks and 3 eyes at 12 weeks. At baseline, 16 eyes (53.33%) demonstrated the presence of SSRD. Among these, 11 eyes showed resolution of SSRD on day 1. SSRD resolved in all patients at 4 weeks and was maintained up to 24 weeks. Conclusions: Ozurdex (R) implant improves the visual outcome of patients with recalcitrant uveitic CME. Reversibility of retinal changes may be possible following treatment with dexamethasone implant. Thus final visual outcome may be independent of pretreatment CMT, the height of CS or SSRD.
引用
收藏
页码:416 / 422
页数:7
相关论文
共 50 条
  • [21] Intravitreal dexamethasone implant Ozurdex® in naive and refractory patients with different subtypes of diabetic macular edema
    Castro-Navarro, Veronica
    Cervera-Taulet, Enrique
    Navarro-Palop, Catalina
    Monferrer-Adsuara, Clara
    Hernandez-Bel, Laura
    Montero-Hernandez, Javier
    BMC OPHTHALMOLOGY, 2019, 19 (1)
  • [22] Structure-function Relationships in Uveitic Cystoid Macular Edema: Using En Face Optical Coherence Tomography to Predict Vision
    Cohen, Liza M.
    Goldstein, Debra A.
    Fawzi, Amani A.
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2016, 24 (03) : 274 - 281
  • [23] Treatment of Non-infectious Uveitic Macular Edema with the Intravitreal Dexamethasone Implant
    Nobre-Cardoso, Joao
    Champion, Emmanuelle
    Darugar, Adil
    Fel, Audrey
    Lehoang, Phuc
    Bodaghi, Bahram
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2017, 25 (04) : 447 - 454
  • [24] Systemic Steroid Sparing Effect of Intravitreal Dexamethasone Implant in Chronic Noninfectious Uveitic Macular Edema
    Fabiani, Claudia
    Vitale, Antonio
    Emmi, Giacomo
    Lopalco, Giuseppe
    Vannozzi, Lorenzo
    Bacherini, Daniela
    Guerriero, Silvana
    Favale, Rosa Anna
    Fusco, Fiorella
    Franceschini, Rossella
    Frediani, Bruno
    Iannone, Florenzo
    Galeazzi, Mauro
    Tosi, Gian Marco
    Cantarini, Luca
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2017, 33 (07) : 549 - 555
  • [25] Dexamethasone intravitreal implant (OZURDEX®) for macular edema secondary to noninfectious uveitis: a review of the literature
    Massa, Horace
    Georgoudis, Panagiotis
    Panos, Georgios D.
    THERAPEUTIC DELIVERY, 2019, 10 (06) : 343 - 351
  • [26] Correlation of Fundus Autofluorescence with Spectral-Domain Optical Coherence Tomography and Vision in Diabetic Macular Edema
    Chung, Hyewon
    Park, Byeongjun
    Shin, Hyun Jin
    Kim, Hyung Chan
    OPHTHALMOLOGY, 2012, 119 (05) : 1056 - 1065
  • [27] Combined Phacoemulsification and Intravitreal Dexamethasone Implant (Ozurdex®) in Diabetic Patients with Coexisting Cataract and Diabetic Macular Edema
    Furino, Claudio
    Boscia, Francesco
    Niro, Alfredo
    Giancipoli, Ermete
    Grassi, Maria Oliva
    Ricci, Giuseppe D'amico
    Blasetti, Francesco
    Reibaldi, Michele
    Alessio, Giovanni
    JOURNAL OF OPHTHALMOLOGY, 2017, 2017
  • [28] Intravitreal dexamethasone implant Ozurdex® in naïve and refractory patients with different subtypes of diabetic macular edema
    Verónica Castro-Navarro
    Enrique Cervera-Taulet
    Catalina Navarro-Palop
    Clara Monferrer-Adsuara
    Laura Hernández-Bel
    Javier Montero-Hernández
    BMC Ophthalmology, 19
  • [29] Clinical and optical coherence tomography biomarkers as prognostic factors in dexamethasone intravitreal implant for diabetic macular edema
    Oliverio, Giovanni William
    Meduri, Alessandro
    Brancati, Valentina Urzi
    Ingrande, Irene
    De Luca, Laura
    Di Raimondo, Enrico
    Minutoli, Letteria
    Aragona, Emanuela
    Aragona, Pasquale
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2024, 34 (06) : 1810 - 1818
  • [30] Intravitreal Dexamethasone Implant (Ozurdex) for Refractory Macular Edema Secondary to Retinitis Pigmentosa
    Ornek, Nurgul
    Ornek, Kemal
    Erbahceci, Inci Elif
    TURK OFTALMOLOJI DERGISI-TURKISH JOURNAL OF OPHTHALMOLOGY, 2016, 46 (04): : 179 - 181